The Therapy of Large Endometrioma
Evaluate the Therapy of Large Ovarian Endometrioma
University Hospital, Lille
62 participants
Jan 21, 2021
OBSERVATIONAL
Conditions
Summary
Endometrioma's prevalence is between 23 and 55%. It causes pelvic pain, decrease fertility and ovarian reserve. Currently, there's no recommendation about large endometrioma's treatment and there's no information on the best treatment to limit recurrences, preserve fertility and ovarian reserve. In Lille university hospital, simple laparoscopic drainage associated with hormonal therapy is practiced to reduce the risk of cystectomy. This protocol will be evaluated with an observational and prospective study, including women of childbearing age having endometrioma measuring 6 cm or above. The aim of this study is to assess if cyst drainage associated with GnRH agonist, could decrease endometrioma recurrences, deleterious effect on ovarian reserve and evaluate impact on anti-mullerian hormone
Eligibility
Inclusion Criteria3
- Endometrioma size ≥ 6cm determined by MRI or ultrasonography
- Women with isolated endometrioma or other extraovarian endometriosis: peritoneal, infiltrating endometriotic lesions and adenomyosis.
- Cyst single or bilateral
Exclusion Criteria6
- Cyst with radiographic or macroscopic in laparoscopy atypia
- Pregnancy
- Patient with contraindication to GnRH agonist (Enantone® 3,75 mg et Decapeptyl® 3 mg)
- Patient with contraindication to laparoscopy
- Patient with contraindication to general anesthesia
- Subject refusing to participate in the study
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04704115